Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Targets October For Quality System Corrections, FDA Re-Inspection

This article was originally published in The Tan Sheet

Executive Summary

Perrigo wants FDA to re-inspect its Allegan, Mich., manufacturing plant in October, when the private labeler intends to have corrected its quality system failings that elicited a warning letter in April
Advertisement

Related Content

Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Reckitt Mucinex Patent Gets Reprieve As Appeals Court Rules Against Perrigo
Reckitt Mucinex Patent Gets Reprieve As Appeals Court Rules Against Perrigo
Reckitt Extends Children's Mucinex Line In Widening Consumer Strategy
Perrigo adds cherry-flavored cetirizine
Perrigo Gets "Wake-Up Call" In FDA Warning Letter
Perrigo Gets "Wake-Up Call" In FDA Warning Letter
Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches

Topics

Advertisement
UsernamePublicRestriction

Register

PS104231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel